Stock market Updates | Sanofi India Ltd. | R Wadiwala Securities Pvt Ltd
NIFTY17617.15  -139.85 (-0.79%)
SENSEX59037.18  -427.44 (-0.72%)
  • top gainers
  • top losers
  • top volume
  • top value
investments Associate Login Online Trading Login
  • indian indices
  • global indices

We are investment service provider for Buy stocks , Low Stocks Brokerage , Stocks Portfolio Management in Surat , NRI Investment in Stocks , Share Broking Surat , Stock Broking Surat , Advisory Services Surat and Competetive Stocks Brokerage. investment advisory, financial integrity and prompt services in the whole of South Gujarat.

L
equity
Home Markets & NewsCompany ProfileSmart Quotes

SANOFI INDIA LTD.

NSE : SANOFIBSE : 500674ISIN CODE : INE058A01010Industry : Pharmaceuticals & DrugsHouse : Sanofi India - MNC
BSE7328.80-99.8 (-1.34 %)
PREV CLOSE (Rs.) 7428.60
OPEN PRICE (Rs.) 7422.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 975
TODAY'S LOW / HIGH (Rs.)7310.00 7422.00
52 WK LOW / HIGH (Rs.)7344 9300
NSE7323.50-77.55 (-1.05 %)
PREV CLOSE( Rs. ) 7401.05
OPEN PRICE (Rs.) 7396.00
BID PRICE (QTY) 7323.50 (2)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 8989
TODAY'S LOW / HIGH(Rs.) 7305.00 7400.00
52 WK LOW / HIGH (Rs.)7056.55 9285

Smart Quotes

BSE NSE
1D 1M 3M 1Y 3Y 5Y
Stock Summary
Trade Value (Rs. in Lacs)
71.57
Dividend Yield(%)
4.98
TTM EPS (Rs.)
424.22
P/E Ratio
17.28
Book Value (Rs.)
927.08
Face Value (Rs.)
10
MCap (Rs. in Mn)
168786.82
Price/Earning (TTM)
16.03
Price/Sales (TTM)
5.65
Price/Book (MRQ)
7.91
PAT Margin (%)
15.64
ROCE (%)
29.77
company info
Incorporation Year : 02-05 1956

Management Info :

Aditya Narayan - Chairman Rajaram Narayanan - Managing Director

Registered Office :

Address : Sanofi House, 117-b,L&t Business Park,Saki Vihar Road, Powai,
Mumbai,
Maharashtra-400072

Phone :

Registrars Details :

Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
News
13Jan Announcement under Regulation 30 (LOD
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
26Nov Divestment Of Soframycin? And Sofrade
Please find enclosed announcement related to - Divestment of Soframycin?..
24Nov Announcement under Regulation 30 (LOD
As required under Regulation 30 of the SEBI (Listing Obligations and Dis..
more
Financials
QTR Sep 21 ANNUAL 20
Net Profit52984776
Gross Profit 6879 6772
Operating Profit 2135 8029
Net Sales 7545 29019
more
Rs. in Millions
Rolling Forward P/E (EOD)
Event Calendar
peer group
Abbott India (BSE)
Rwadiwala-peer-arrow  16987.05 (0.87%)
M.Cap (Rs. in Cr)36096.30
Ajanta Pharma (BSE)
Rwadiwala-peer-arrow  2215.95 (3.01%)
M.Cap (Rs. in Cr)19175.89
Fredun Pharma (BSE)
Rwadiwala-peer-arrow  1094.30 (5.00%)
M.Cap (Rs. in Cr)485.06
Alkem Laboratories (BSE)
Rwadiwala-peer-arrow  3555.50 (1.02%)
M.Cap (Rs. in Cr)42511.34
Shareholding Pattern
FI/BANKS/INSURANCE
8.36%
PROMOTERS
60.4%
NON-INSTITUTION
11.33%
MUTUAL FUNDS/UTI
10.67%
GOVERNMENT
0%
FII
0%
more
Mf Holdings
ATTENTION INVESTORS|KYC|IPO|PROPRIETARY TRADING
Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors.    
ATTENTION INVESTORS Advisory for Investors Advisory - KYC Compliance
  • 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.
  • 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • 3. Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors
CORPORATE OFFICE
address
  • 9/2003-4,
  • Vishnu Priya Limda Chowk
  • Main Road
  • Surat – 395 003.
fax us @ +91-261-6673537
email us @ info@rwadiwala.com

Feed Back  | Terms & Conditions  | SEBI  | FMC  | NSE  | BSE  |  Advisory For Investors  |  MCX  | NCDEX  | IRDA  |  AMFI  | Disclaimer  | Privacy Policy  | Careers | User Agreements  | Ethics Policy  | Investor Protection  |  Dos and Don'ts   |  Rights and Obligations   |  Uniform Risk Disclosure   |   Important Policies   |  Investor Charter   | To File A Complaint on SCORES   | Sitemap 

SEBI Regn No. BSE - CM/F&O, NSE - CM/F&O/CDS: INZ000187332 | SEBI PMS regn no.: INP000004045 | MCX & NCDEX SEBI Regn No.: INZ000080636 | CDSL DP ID: 12043100
| R Wadiwala Securities Pvt Ltd - CIN: U67120GJ2004PTC044324 | R Wadiwala Commodities Pvt Ltd - CIN: U51109GJ2007PTC050176

Compliance Officer - Email ID: compliance@rwadiwala.com | Contact No.: 0261-6673542

The Stock Exchange, Mumbai is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time. The Stock Exchange, Mumbai is not answerable, responsible or liable for any information on this Website or for any services rendered by us, our employees, and our servants.

Investor Greivance Redressal at support@rwadiwala.com

Copyright © 2016 | All Rights Reserved. R.Wadiwala group.

Designed & Developed by ●●● Accord Fintech Pvt. Ltd.